AIM ImmunoTech amends ATM agreement to remove $3M cap on share sales

AIM ImmunoTech Inc.

Amendment No. 1 to Equity Distribution Agreement with Maxim Group removes the prior $3,000,000 limit on shares sold.
Company's common stock continues to be offered at-the-market under existing shelf registration statement (Form S-3).
A prospectus supplement was filed to increase the number of shares available for sale in the offering.
Maxim Group remains the exclusive sales agent for the at-the-market offering.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

AIM ImmunoTech Inc. amended Amendment No. 1 with Maxim Group LLC (effective 2026-04-10).

Action: amendment
Agreement: atm program
Counterparty: Maxim Group LLC
Effective: 2026-04-10

Exact text from the filing

On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).

View on SEC.gov

Browse all material agreements →

AIM ImmunoTech Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-016179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.